## Review setup
- **Input scope** Full manuscript text including abstract, background, methods, results, discussion, and supplementary figure legends as provided.
- **Assessment boundary** Scientific content, experimental design, data interpretation, and claims as presented in the provided text. No access to actual figures, raw data, or supplementary files beyond what is described.
- **Shared manuscript claim summary** The authors propose that the long noncoding RNA PVT1 promotes cuproptosis in colorectal cancer by transcriptionally activating FDX1 through direct binding to the FDX1 promoter, increasing H3K27ac deposition, and recruiting the transcription factor SF1. They further claim that this axis sensitizes tumors to copper-dependent cell death and represents a therapeutic target and biomarker.
- **Visible evidence base** Text descriptions of results from cell viability assays, colony formation, western blotting, immunofluorescence, ChIRP, ChIP, RIP, luciferase reporter assays, bioinformatics analyses, and mouse xenograft experiments. Figure legends are referenced but figures themselves are not available for direct inspection.
- **Missing materials affecting confidence** Actual figures and supplementary data files are not provided. Raw numerical data, statistical outputs, and detailed experimental protocols are not fully available. The manuscript text alone is insufficient to verify the magnitude and quality of the reported effects.

## Reviewer
- **Overall assessment** The manuscript addresses a timely and potentially interesting question, namely how cuproptosis sensitivity is regulated at the transcriptional level in colorectal cancer. The identification of PVT1 as an upstream activator of FDX1 is conceptually novel and could have translational relevance. However, the evidence as presented in the text is largely descriptive and correlative, and several key mechanistic claims are not fully substantiated by the data described. The reliance on bioinformatic predictions and in vitro overexpression or knockdown systems without orthogonal validation weakens the conclusions. The in vivo experiments are limited to xenograft models with a single cell line and do not include clinically relevant copper ionophore dosing or pharmacokinetic analysis. The claim that PVT1 recruits SF1 to the FDX1 promoter is supported only by indirect assays, and the functional significance of this interaction is not rigorously established. Overall, the study is promising but currently does not provide a fully convincing mechanistic case.

- **Who would be interested in the results, and why** Researchers studying regulated cell death, particularly cuproptosis, and those interested in the role of long noncoding RNAs in cancer biology would find this work relevant. The potential clinical implication of using PVT1 expression as a biomarker for cuproptosis-based therapy could also attract translational oncology investigators. However, the narrow focus on colorectal cancer and the lack of generalizable mechanistic insight may limit broader interest.

- **Major strengths**
  - The study addresses a relatively unexplored area, namely the transcriptional regulation of FDX1, a core cuproptosis mediator.
  - The combination of bioinformatic screening, molecular assays, and in vivo xenograft experiments provides a multi-level approach.
  - The identification of a specific PVT1 region and FDX1 promoter region involved in the interaction adds mechanistic detail.
  - The potential clinical relevance of PVT1 as a predictive biomarker for cuproptosis sensitivity is an interesting translational angle.

- **Major Concerns**

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence quality and reproducibility
- **Claim pointer** The authors claim that PVT1 directly binds to the FDX1 promoter region at −104/−41 bp and that this binding is required for transcriptional activation.
- **Evidence pointer** Results section, Figure 4, ChIRP-qPCR and luciferase reporter assays
- **Concern** The ChIRP assay is described but the specificity of the probes, the efficiency of pull-down, and the enrichment levels are not reported. The luciferase reporter assay with a deletion construct is a reasonable approach, but the text does not state whether the deletion affects basal promoter activity independently of PVT1. Without these controls, the claim of direct binding and functional requirement is not fully supported.
- **Why it matters** Direct binding of a lncRNA to a DNA promoter region is a strong mechanistic claim that requires rigorous biochemical validation. If the binding is not specific or the deletion affects promoter integrity, the entire model of PVT1-mediated transcriptional activation is weakened.
- **Resolution test** Provide ChIRP data with negative control probes and demonstrate that the FDX1 promoter deletion does not alter basal transcriptional activity. Include a chromatin isolation experiment with a mutated PVT1 lacking the predicted binding region to show loss of promoter occupancy.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Mechanistic completeness
- **Claim pointer** The authors claim that PVT1 recruits the transcription factor SF1 to the FDX1 promoter, and that SF1 is required for PVT1-mediated FDX1 transcription.
- **Evidence pointer** Results section, Figure 6, RIP, ChIP, and knockdown experiments
- **Concern** The interaction between PVT1 and SF1 is shown by RIP and ChIRP, but the text does not describe whether the PVT1-SF1 interaction is direct or mediated by other proteins. The ChIP experiment shows SF1 occupancy at the FDX1 promoter, but it is not demonstrated that this occupancy is dependent on PVT1. The knockdown of SF1 reduces FDX1 expression, but the rescue experiment with PVT1 overexpression in the SF1 knockdown background is not described. Without these experiments, the claim that PVT1 acts through SF1 is not fully established.
- **Why it matters** The proposed model is that PVT1 recruits SF1 to activate FDX1 transcription. If SF1 occupancy is independent of PVT1, or if PVT1 can activate FDX1 in the absence of SF1, the model is incorrect. The mechanistic chain must be complete to support the central claim.
- **Resolution test** Perform a ChIP experiment for SF1 at the FDX1 promoter in PVT1 knockdown and overexpression conditions. Conduct a rescue experiment where SF1 is knocked down and PVT1 is overexpressed to determine if PVT1 can still enhance FDX1 expression. Use an in vitro binding assay to test direct PVT1-SF1 interaction.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** In vivo relevance and therapeutic claim
- **Claim pointer** The authors claim that the PVT1-FDX1 axis is a promising therapeutic target and that PVT1 increases tumor sensitivity to cuproptosis in vivo.
- **Evidence pointer** Results section, Figure 8, xenograft experiments
- **Concern** The xenograft experiments are performed with a single cell line (HCT116) and a single treatment regimen. The text does not describe the dosing schedule, the route of administration, or whether the copper ionophore concentration used is clinically achievable. The claim of therapeutic relevance is based on tumor volume and weight measurements, but no survival data or long-term toxicity assessment is provided. The translational claim is therefore overstated relative to the evidence.
- **Why it matters** A therapeutic claim requires evidence that the treatment is effective and safe in a relevant model. A single xenograft experiment with one cell line is insufficient to support the conclusion that targeting the PVT1-FDX1 axis is a viable therapeutic strategy.
- **Resolution test** Include additional cell lines and patient-derived xenografts. Provide detailed treatment protocols, including dose, route, and schedule. Assess toxicity and survival. If possible, use a copper ionophore that is already in clinical use to strengthen translational relevance.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Statistical rigor and data presentation
- **Claim pointer** The authors state that differences were statistically significant, but the text does not describe the statistical tests used, the number of biological replicates, or the dispersion of the data.
- **Evidence pointer** Throughout Results, figure legends
- **Concern** The figure legends mention statistical significance but do not specify the test, the sample size, or whether the data are presented as mean ± SD or SEM. The text states "three times of independent experiments" but does not clarify whether these are technical or biological replicates. Without this information, the robustness of the findings cannot be assessed.
- **Why it matters** Statistical rigor is essential for the credibility of the conclusions. The lack of detail prevents the reader from evaluating whether the effects are reproducible and meaningful.
- **Resolution test** Provide a detailed statistical analysis section, including the tests used, the number of replicates, and the exact p-values. Present data as scatter plots with individual data points where possible.

- **Minor Comments**

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity of writing
- **Affected element** Abstract and Background
- **Evidence pointer** Abstract, Background section
- **Issue** The abstract states that PVT1 promotes cuproptosis, but the background does not clearly explain why cuproptosis is relevant to colorectal cancer specifically, nor does it discuss the clinical context of copper levels in CRC.
- **Required correction** Add a brief statement in the Background about copper dysregulation in CRC and why cuproptosis is a relevant vulnerability in this cancer type.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Methodological detail
- **Affected element** Cell viability and apoptosis assay
- **Evidence pointer** Methods, Cell viability and apoptosis assay
- **Issue** The text mentions an apoptosis assay in the section title but does not describe any apoptosis-specific experiments in the Results. The CCK-8 and colony formation assays measure viability and proliferation, not apoptosis.
- **Required correction** Either add apoptosis data (e.g., Annexin V staining, caspase activity) or rename the section to reflect the assays actually performed.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Data interpretation
- **Affected element** Figure 1D and E
- **Evidence pointer** Results, Figure 1D and E
- **Issue** The text states that inhibitors of apoptosis, ferroptosis, and autophagy failed to prevent cell death, but the concentrations of these inhibitors are not provided. It is possible that the inhibitors were used at suboptimal concentrations.
- **Required correction** Provide the concentrations of the inhibitors used and include a positive control to demonstrate that the inhibitors are effective at the concentrations used.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Clinical relevance
- **Affected element** Discussion
- **Evidence pointer** Discussion section
- **Issue** The discussion mentions the potential for combination therapy with copper ionophores and standard chemotherapy, but does not discuss potential toxicity or the challenges of delivering copper to tumors.
- **Required correction** Add a paragraph discussing the challenges and potential side effects of copper-based therapies, and how the proposed approach might overcome these.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Figure quality
- **Affected element** Figure 4K
- **Evidence pointer** Results, Figure 4K
- **Issue** The molecular docking model is described but the figure is not available for review. The text states that hydrogen bonds are highlighted, but the quality of the model and the significance of the docking score are not discussed.
- **Required correction** Provide the docking scores for all models and discuss the significance of the top model. If possible, validate the predicted interaction with a mutagenesis experiment.

- **Technical failings that need to be addressed before the case is established**
  - R1-M1: Direct binding of PVT1 to the FDX1 promoter requires more rigorous validation, including appropriate controls and a demonstration of specificity.
  - R1-M2: The role of SF1 in PVT1-mediated FDX1 transcription is not fully established. The dependence of SF1 promoter occupancy on PVT1 and the functional requirement of SF1 for PVT1 activity need to be demonstrated.
  - R1-M3: The in vivo therapeutic claim is based on a single xenograft model and lacks sufficient detail on dosing and toxicity. The translational relevance is overstated.
  - R1-M4: Statistical details are insufficient to evaluate the robustness of the data.

- **Assessment against Nature-style criteria**
  - **Originality** The concept of a lncRNA regulating cuproptosis by transcriptionally activating FDX1 is novel. However, the general idea that lncRNAs regulate gene expression in cancer is well established, and the specific novelty is incremental rather than paradigm-shifting.
  - **Scientific importance** The study provides a potential mechanism for regulating cuproptosis sensitivity, which is a topic of growing interest. However, the importance is limited by the lack of generalizability beyond colorectal cancer and the absence of a clear demonstration that this axis is clinically relevant.
  - **Interdisciplinary readership** The topic is likely to appeal to cancer biologists and those studying regulated cell death. The potential therapeutic implications may attract translational researchers, but the narrow focus and lack of broad mechanistic insight may limit wider interest.
  - **Technical soundness** The experimental design is generally reasonable, but several key claims are not fully supported by the data as described. The lack of statistical detail and the reliance on single assays for key conclusions reduce the technical soundness.
  - **Readability for nonspecialists** The manuscript is written in a clear and accessible style, with a logical flow from background to results to discussion. However, the heavy reliance on specialized techniques and the lack of context for some assays may make it challenging for nonspecialists to fully appreciate the findings.

- **Recommendation posture** Currently not established from the provided evidence. The study addresses an interesting question and has potential, but the mechanistic claims are not fully supported by the data as presented. The authors need to provide additional experimental evidence to substantiate the direct binding of PVT1 to the FDX1 promoter, the role of SF1, and the therapeutic relevance of the axis. If these concerns are addressed with rigorous experiments, the manuscript could become a valuable contribution to the field.

## Risk / unsupported claims
- The claim that PVT1 directly binds to the FDX1 promoter at the −104/−41 bp region is not fully supported without appropriate controls and specificity data.
- The claim that PVT1 recruits SF1 to the FDX1 promoter is based on indirect evidence and requires direct demonstration of the interaction and its functional significance.
- The claim that the PVT1-FDX1 axis is a promising therapeutic target is overstated given the limited in vivo data and lack of toxicity and dosing information.
- The claim that PVT1 increases tumor sensitivity to cuproptosis in vivo is based on a single xenograft experiment and requires validation in additional models.
- The statistical significance of the results cannot be fully assessed due to the lack of detailed statistical methods and data presentation.